Skip to content
sellWeak cluster of 710b5-1 plan

Arthur F Ryan sold $90k of REGN

director at REGENERON PHARMACEUTICALS, INC.. 100 shares at an average of $899.90, traded Jan 2, 2024, filed Jan 4, 2024.

Warning score
19
Value
$90k
100 shares
Holdings after
18,347
-1% from before
From 52-week low
+33%
low $674.13, close $896.54
From 52-week high
0%
high $896.54, as of Jan 2, 2024

Score components

  • Role
    Director
    +15
  • Trade size
    $90k at market
    +9
  • Share of holdings sold
    Sold 0.5% of holdings
    0
  • Cluster
    7 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

REGNOct 9, 2026 · close 746.54
Since filing Jan 4, 2024: -17.4%SPY +71.9% · excess -89.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001968202-24-000025, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-1$873.91$87418,446Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-2$886.26$1,77318,444Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-1$887.13$88718,443Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-1$892.00$89218,442Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-8$896.47$7,17218,434Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-3$897.41$2,69218,431Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-6$898.76$5,39318,425Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-14$899.66$13k18,411Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-29$900.59$26k18,382Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-9$901.46$8,11318,373Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-10$902.37$9,02418,363Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-13$903.49$12k18,350Jan 4, 2024
Jan 2, 2024SOpen-market sale
Common Stock10b5-1
-3$904.49$2,71318,347Jan 4, 2024
Jan 2, 2024AGrant or award
Common Stock10b5-1
+135$0.00$018,482Jan 4, 2024
Jan 2, 2024AGrant or award
Non-Qualified Stock Option (right to buy)derivative10b5-1
+1,607$0.00$01,607Jan 4, 2024

Related signals

Other insiders at REGENERON PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
13Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Kathryn Guarini
director
$340k
400 shares
-40%
33Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Marion McCourt
EVP Commercial
$2.0M
2,346 shares
-16%
12Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Kathryn Guarini
director
$320k
400 shares
-40%
18Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Huda Y Zoghbi
director
$640k
800 shares
-32%
6Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$130k
200 shares
-1%
3Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$71k
100 shares
-1%
4Weak
REGNsell10b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$78k
100 shares
-1%
12Weak
REGNsell 210b5-1
REGENERON PHARMACEUTICALS, INC.
Arthur F Ryan
director
$79k
100 shares
-1%
30Weak
REGNsell 310b5-1
REGENERON PHARMACEUTICALS, INC.
Huda Y Zoghbi
director
$1.3M
1,638 shares
-49%
30Weak
REGNsell 310b5-1
REGENERON PHARMACEUTICALS, INC.
Jason Pitofsky
SVP Controller
$1.6M
2,036 shares
-32%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Arthur F Ryan sold $90k of REGN | InsiderTell